Vascular Biogenics (VBLT) Hits New 12-Month High and Low at $2.15

Vascular Biogenics Ltd (NASDAQ:VBLT)’s share price reached a new 52-week high and low on Monday . The stock traded as low as $2.15 and last traded at $2.17, with a volume of 444905 shares changing hands. The stock had previously closed at $2.30.

Several research firms have recently weighed in on VBLT. HC Wainwright set a $3.00 target price on Vascular Biogenics and gave the company a “hold” rating in a research report on Thursday, March 22nd. Piper Jaffray downgraded Vascular Biogenics from an “overweight” rating to a “neutral” rating and set a $4.00 target price on the stock. in a research report on Thursday, March 8th. ValuEngine downgraded Vascular Biogenics from a “sell” rating to a “strong sell” rating in a research report on Friday, March 9th. Zacks Investment Research raised Vascular Biogenics from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Saturday, March 17th. Finally, JMP Securities downgraded Vascular Biogenics from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 8th. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. Vascular Biogenics presently has an average rating of “Hold” and an average price target of $3.19.

How to Become a New Pot Stock Millionaire

The stock has a market cap of $68.76, a price-to-earnings ratio of -5.95 and a beta of -1.67.

Vascular Biogenics (NASDAQ:VBLT) last released its earnings results on Thursday, March 15th. The biopharmaceutical company reported $0.24 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.05 by $0.19. The company had revenue of $13.86 million for the quarter. equities research analysts forecast that Vascular Biogenics Ltd will post -0.81 EPS for the current year.

A number of institutional investors have recently made changes to their positions in the business. Raymond James & Associates grew its position in Vascular Biogenics by 71.5% in the 4th quarter. Raymond James & Associates now owns 55,466 shares of the biopharmaceutical company’s stock valued at $394,000 after acquiring an additional 23,124 shares during the last quarter. ARK Investment Management LLC bought a new position in Vascular Biogenics in the 4th quarter valued at $302,000. Alps Advisors Inc. bought a new position in Vascular Biogenics in the 4th quarter valued at $234,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Vascular Biogenics in the 3rd quarter valued at $135,000. Finally, IFP Advisors Inc grew its position in Vascular Biogenics by 339.7% in the 4th quarter. IFP Advisors Inc now owns 19,567 shares of the biopharmaceutical company’s stock valued at $139,000 after acquiring an additional 15,117 shares during the last quarter. 5.58% of the stock is currently owned by institutional investors.

WARNING: “Vascular Biogenics (VBLT) Hits New 12-Month High and Low at $2.15” was posted by Enterprise Leader and is owned by of Enterprise Leader. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://theenterpriseleader.com/2018/04/02/vascular-biogenics-vblt-hits-new-12-month-high-and-low-at-2-15.html.

About Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply